Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nituzumab plus first-line chemotherapy for advanced esophageal squamous cell carcinoma (Phase II, single-arm)
ChiCTR2200057917Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoints: Objective response rate of tumor (ORR), Overall tumor survival (OS) and 4 more. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2200057917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057917.